Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., and investors have until September 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2]. Group 3: Financial Impact - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut occurred on July 8, 2025, due to slower LAL utilization and adoption challenges, resulting in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against GeneDx Holdings Corp. for possible violations of federal securities laws and unlawful business practices [1][3] Group 1: Allegations Against GeneDx - A report by Grizzly Research claims that GeneDx's growth is largely an illusion, driven by fraudulent schemes aimed at exploiting Medicaid and Medicare systems to inflate revenue [3] - The report alleges that GeneDx has engaged in "code stacking," allowing the company to bill insurance providers for services that do not meet required criteria [3] - It is noted that CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, suggesting insider knowledge of imminent risks [3] Group 2: Stock Price Impact - Following the allegations, GeneDx's stock price fell by $4.84 per share, or 6.72%, closing at $67.18 per share on February 5, 2025 [3] Group 3: Legal Options for Investors - Bragar Eagel & Squire encourages investors who suffered losses in GeneDx to contact them to discuss their legal rights and options [1][4]

Core Viewpoint - Marex Group plc is under investigation for potential violations of federal securities laws following allegations of a multi-year accounting scheme that concealed significant losses and inflated profits [1][2]. Group 1: Allegations and Financial Impact - A report by NINGI Research claims that Marex has concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund, which it controls and trades with [2]. - The report also alleges that Marex misclassified structured note issuance as income to inflate operating cash flow and generate non-cash trading profits [2]. - Following the news, Marex's stock price dropped by $2.33, or 6.2%, closing at $35.31 per share on August 5, 2025, resulting in financial injury to investors [3]. Group 2: Legal and Whistleblower Information - Glancy Prongay & Murray LLP is leading the investigation on behalf of Marex investors and is encouraging those with non-public information to consider aiding the investigation through the SEC Whistleblower Program, which offers rewards up to 30% of any successful recovery [5]. - The law firm has a strong track record in securities litigation, having been consistently ranked among the top firms in terms of settlements and recoveries for investors [6][7].

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for alleged violations of securities laws, specifically related to misleading statements about a Department of Justice investigation [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to Semler's actions between March 10, 2021, and April 15, 2025, during which investors are encouraged to contact the Schall Law Firm if they suffered losses [2]. - The complaint alleges that Semler made false and misleading statements regarding a DOJ investigation into potential violations of the False Claims Act, which were not disclosed to investors [4]. Group 2: Investor Participation - Investors who purchased Semler's securities during the class period are invited to join the lawsuit to recover their losses, with a deadline for participation set for October 29, 2025 [2]. - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [4].

Core Viewpoint - A class action securities lawsuit has been filed against PubMatic, Inc. alleging securities fraud that negatively impacted investors between February 27, 2025, and August 11, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that PubMatic's management made false statements and concealed critical information regarding a major demand side platform buyer shifting clients to a new platform, leading to reduced ad spend and revenue for PubMatic [2]. - The lawsuit asserts that the positive statements made by the defendants about PubMatic's business and prospects were materially misleading and lacked a reasonable basis due to the aforementioned issues [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 20, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Flywire Corporation, alleging securities fraud that affected investors between February 28, 2024, and February 25, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Flywire's revenue growth was overstated, and the negative impact of permit and visa-related restrictions on its business was understated [2]. - Defendants' public statements regarding Flywire were allegedly materially false and misleading throughout the relevant period [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 23, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Law Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

SAN FRANCISCO, Sept. 2, 2025 /PRNewswire/ -- A securities fraud class action lawsuit styled Liggett Sr. v. C3.ai, Inc., et al., No. 3:25-cv-07129 (N.D. Cal.) has been filed and seeks to represent C3.ai (NYSE: AI) investors who purchased or otherwise acquired C3.ai securities between February 26, 2025 and August 8, 2025.The lawsuit comes after C3.ai reported preliminary financial results for its Q1 2026, which shockingly included expected revenues between only $70.2 million-$70.4 million, well below the midp ...

Core Viewpoint - A securities class action lawsuit has been filed against Replimune Group, Inc. for allegedly making materially false and misleading statements regarding its business and product prospects during the specified class period from November 22, 2024, to July 21, 2025 [1][2]. Group 1: Allegations Against Replimune - The complaint claims that Replimune overstated the trial prospects for its lead product candidate [2]. - It is alleged that the statements made by the defendants about the company's business, operations, and prospects were materially false and misleading, lacking a reasonable basis throughout the class period [2]. Group 2: Lead Plaintiff Process - Investors in Replimune have until September 22, 2025, to seek appointment as a lead plaintiff representative of the class [3]. - The lead plaintiff will act on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has recovered billions for victims of fraud and corporate misconduct [4]. - The firm encourages Replimune investors who have suffered significant losses to contact them for more information [4].

Core Viewpoint - A securities fraud class action lawsuit has been filed against C3.ai, Inc. for alleged misrepresentations regarding the company's business and the impact of the CEO's health on its operations [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Northern District of California on behalf of investors who acquired C3 securities between February 26, 2025, and August 8, 2025 [3]. - Allegations include that the CEO's health significantly affected C3 AI's ability to close deals and that management failed to mitigate this impact, hindering the company's profit and growth potential [4]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by October 21, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of RxSight, Inc. (NASDAQ: RXST)?Did you purchase your shares between November 7, 2024 and July 8, 2025, inclusive?Did you lose money in you ...